Under construction – not a live service

Skip to content

Frontlight Research

Institution

Fox Chase Cancer Center

Philadelphia, United StateshealthcareWebsite

231running trials
106closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Recruiting
Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer
NCT07908979· Phase 2· Source
Recruiting
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
NCT07768189· Phase 3· Source
Recruiting
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin
NCT07441681· Phase 3· Source
Recruiting
Prehabilitation in High-risk Oncologic Surgery
NCT07638410· Source
Not yet recruiting
AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)
NCT07640737· Phase 2· Source
Recruiting
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
NCT07542704· Phase 1· Source
Recruiting
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266· Phase 3· Source
Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
NCT07422480· Phase 3· Source
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295· Phase 3· Source
Recruiting
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
NCT07068074· Phase 3· Source
Recruiting
Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas
NCT07455032· Phase 1· Source
Recruiting
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
NCT07057791· Phase 2· Source
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· Phase 3· Source
Recruiting
Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
NCT07221942· Phase 2· Source
Recruiting
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
NCT07195682· Phase 1· Source
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· Phase 3· Source
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· Phase 3· Source
Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· Phase 3· Source
Recruiting
Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis
NCT06794229· Phase 2· Source
Recruiting
Adaptive Radiation Boost for Rectal Cancer
NCT07221058· Phase 1· Source
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791· Phase 1· Source
Recruiting
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
NCT07167446· Early phase 1· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· Source
Recruiting
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
NCT06966024· Phase 1· Source
Recruiting
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
NCT06984562· Source
Recruiting
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer
NCT06356155· Phase 2· Source
Recruiting
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
NCT07000084· Phase 3· Source
Recruiting
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
NCT07043972· Phase 2· Source
Active, not recruiting
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556· Phase 2· Source
Active, not recruiting
CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen
NCT06699836· Phase 2· Source
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· Phase 3· Source
Recruiting
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
NCT06616584· Phase 2/3· Source
Recruiting
SLV-154 Treatment of Advanced Cancers
NCT06771219· Phase 1· Source
Recruiting
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
NCT06809140· Phase 2· Source
Recruiting
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863· Phase 1· Source
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670· Phase 2/3· Source
Active, not recruiting
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236· Phase 3· Source
Active, not recruiting
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316· Phase 1/2· Source
Recruiting
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126· Phase 3· Source
Recruiting
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
NCT06660355· Phase 2· Source
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094· Phase 3· Source
Active, not recruiting
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984· Phase 3· Source
Recruiting
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318· Phase 3· Source
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· Phase 3· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556· Phase 3· Source
Active, not recruiting
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951· Phase 1· Source
Recruiting
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806· Phase 3· Source
Recruiting
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916· Phase 3· Source
Recruiting
Reducing Urban Cervical Cancer Disparities
NCT06416150· Source
Recruiting
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
NCT06396533· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer16 recruiting
Bladder cancer12 recruiting
Head and neck cancer10 recruiting
Colorectal cancer9 recruiting
Melanoma8 recruiting
Childhood cancers7 recruiting
Ovarian cancer7 recruiting
Pancreatic cancer6 recruiting
Prostate cancer5 recruiting
Sarcoma4 recruiting
Cervical cancer3 recruiting
Gastric and esophageal cancer3 recruiting
Kidney cancer3 recruiting
Neuroendocrine tumours3 recruiting
Multiple myeloma2 recruiting
Myeloproliferative neoplasms2 recruiting
Acute myeloid leukemia1 recruiting
Chronic lymphocytic leukaemia1 recruiting
Chronic myeloid leukaemia1 recruiting
Diffuse large B-cell lymphoma1 recruiting
Endometrial cancer1 recruiting
Follicular lymphoma1 recruiting
Liver and biliary tract cancer1 recruiting
Metastatic breast cancer1 recruiting
Myelodysplastic syndromes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

Terminated
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT06790966· Phase 3· Source
Recruiting
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT06515613· Phase 1· Source
Completed
Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study
NCT06234488· Source
Terminated
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
NCT05883449· Phase 2· Source
Completed
HPV Self-sampling for Underscreened Latinas
NCT06439706· Source
Terminated
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
NCT05617040· Phase 1/2· Source
Terminated
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
NCT05420636· Phase 2· Source
Completed
African Cancer Genome: GMD
NCT05754658· Source
Completed
Study of DF9001 in Patients With Advanced Solid Tumors
NCT05597839· Phase 1/2· Source
Completed
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05287113· Phase 2· Source
Withdrawn
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
NCT05400577· Phase 2· Source
Terminated
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
NCT05079230· Phase 3· Source
Terminated
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
NCT05070247· Phase 1/2· Source
Terminated
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
NCT05242822· Phase 1· Source
Terminated
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT05252390· Phase 1· Source
Completed
Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue
NCT04972097· Source
Terminated
A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
NCT05181540· Phase 3· Source
Completed
A Study of PRT2527 in Participants With Advanced Solid Tumors
NCT05159518· Phase 1· Source
Recruiting
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
NCT05125016· Phase 1/2· Source
Completed
A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment
NCT05014412· Phase 2· Source
Terminated
KZR-261 in Subjects With Advanced Solid Malignancies
NCT05047536· Phase 1· Source
Terminated
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
NCT04221438· Phase 2· Source
Withdrawn
Local Consolidative Therapy in Colorectal Cancer
NCT05062720· Phase 2· Source
Completed
PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2
NCT04815876· Source
Recruiting
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560· Phase 1/2· Source
Completed
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
NCT04880434· Phase 2· Source
Completed
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
NCT04260126· Phase 2· Source
Completed
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
NCT04704219· Phase 2· Source
Completed
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
NCT04649359· Phase 2· Source
Completed
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
NCT04620330· Phase 2· Source
Recruiting
Collection of Samples USOPTIVAL Study
NCT04792684· Source
Completed
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
NCT04338399· Phase 3· Source
Completed
Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
NCT04387461· Phase 2· Source
Terminated
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
NCT04383210· Phase 2· Source
Completed
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
NCT04489771· Phase 2· Source
Completed
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
NCT04526106· Phase 1/2· Source
Terminated
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
NCT04459715· Phase 3· Source
Completed
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
NCT04428151· Phase 2· Source
Terminated
Futibatinib in Patients With Specific FGFR Aberrations
NCT04189445· Phase 2· Source
Terminated
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
NCT04338269· Phase 3· Source
Completed
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT04332653· Phase 1/2· Source
Completed
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
NCT04102020· Phase 3· Source
Terminated
A Study of TAS1440 With ATRA in Subjects With r/r AML
NCT04282668· Phase 1· Source
Completed
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
NCT04173507· Phase 2· Source
Completed
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
NCT04209855· Phase 3· Source
Completed
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
NCT04109924· Phase 2· Source
Completed
Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
NCT04096638· Phase 1· Source
Completed
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
NCT03929666· Phase 2· Source
Terminated
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
NCT03737994· Phase 2· Source
Completed
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
NCT03976375· Phase 3· Source

Trial sites

Fox Chase Cancer Center308 trials
Fox Chase Cancer Center (Data Collection Only)1 trial
Fox Chase Cancer Center /ID# 2239551 trial
Fox Chase Cancer Center /ID# 2393721 trial
Fox Chase Cancer Center /ID# 2421061 trial
Fox Chase Cancer Center - Philadelphia11 trials
Fox Chase Cancer Center (Site 0006)1 trial
Fox Chase Cancer Center (Site 0011)1 trial
Fox Chase Cancer Center (Site 0019)1 trial
Fox Chase Cancer Center (Site 0026)1 trial
Fox Chase Cancer Center (Site 0055)1 trial
Fox Chase Cancer Center (Site 0063)1 trial
Fox Chase Cancer Center (Site 0076)1 trial
Fox Chase Cancer Center (Site 0106)1 trial
Fox Chase Cancer Center (Site 0111)1 trial
Fox Chase Cancer Center (Site 0830)1 trial
Fox Chase Cancer Center Site#1121 trial
Fox Chase Cancer Center (Site 1433)1 trial
Fox Chase Cancer Center (Site 1502)1 trial
Fox Chase Cancer Center (Site 1506)1 trial
Fox Chase Cancer Center (Site 1647)1 trial
Fox Chase Cancer Center - Temple Health1 trial
Temple University - Fox Chase Cancer Center1 trial
Fox Chase Cancer Center-Rockledge2 trials

Conditions

Diseases this institution publishes on or runs trials for.

Bladder cancer28 works · 32 trials
Kidney cancer27 works · 21 trials
Hodgkin lymphoma14 works · 8 trials
Head and neck cancer11 works · 38 trials
Mantle cell lymphoma9 works · 4 trials

Institution data: ROR 0567t7073 (CC0-1.0)Updated 10 Nov 2026

Report an error